PHARMACOLOGICAL RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向：肿瘤 经验分享：邀请了8个审稿人，一周了没人接受审稿，哎，啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601231, encodeId=8898601231d3, content=审稿速度:1.0 经验分享：难啊，又被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8ca15329448, createdName=jack123123, createdTime=Wed Jun 03 07:29:34 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=903771, encodeId=7691903e710a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肝癌;药效;靶向治疗 经验分享：注重创新性，审稿很快，效率很高，一审20天，提的意见不多，两个review都肯定了我们的工作，给了一个月补实验，三个星期补完实验，给语言公司润色，当天中午上传修回稿，第二天上午就接受了，简直神速, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Tue Dec 01 09:30:12 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省)]

2022-07-24 石烽

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：主动脉夹层
经验分享：5.3 Submitted to Journal
5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段)
5.10 Under Review
6.10 Required Reviews Completed
6.12 Decision in Process
6.14 Major Revise (20天期限)
7.2 Resubmitted to Journal
7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段)
7.11 Under Review
7.20 Required Reviews Completed
7.20 Decision in Process
7.23 Accept
7.23 Pre-proof online (DOI )
要点：
1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。
2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。
3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核
祝各位的Paper早日Accept !!!

130 39

展开39条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向：肿瘤 经验分享：邀请了8个审稿人，一周了没人接受审稿，哎，啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601231, encodeId=8898601231d3, content=审稿速度:1.0 经验分享：难啊，又被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8ca15329448, createdName=jack123123, createdTime=Wed Jun 03 07:29:34 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=903771, encodeId=7691903e710a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肝癌;药效;靶向治疗 经验分享：注重创新性，审稿很快，效率很高，一审20天，提的意见不多，两个review都肯定了我们的工作，给了一个月补实验，三个星期补完实验，给语言公司润色，当天中午上传修回稿，第二天上午就接受了，简直神速, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Tue Dec 01 09:30:12 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省)]

2020-12-02 泪湿青衣

审稿速度:1.0 | 投稿命中率:75.0
经验分享：一审20天，给了一个月修回，修回后第二天立马接收了

360 33

展开33条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向：肿瘤 经验分享：邀请了8个审稿人，一周了没人接受审稿，哎，啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601231, encodeId=8898601231d3, content=审稿速度:1.0 经验分享：难啊，又被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8ca15329448, createdName=jack123123, createdTime=Wed Jun 03 07:29:34 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=903771, encodeId=7691903e710a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肝癌;药效;靶向治疗 经验分享：注重创新性，审稿很快，效率很高，一审20天，提的意见不多，两个review都肯定了我们的工作，给了一个月补实验，三个星期补完实验，给语言公司润色，当天中午上传修回稿，第二天上午就接受了，简直神速, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Tue Dec 01 09:30:12 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省)]

2020-12-12 ms1000001706153386

审稿速度:1.0 | 投稿命中率:50.0
经验分享：一审15天，一周修回，2小时后accept，效率奇高

391 20

展开20条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向：肿瘤 经验分享：邀请了8个审稿人，一周了没人接受审稿，哎，啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601231, encodeId=8898601231d3, content=审稿速度:1.0 经验分享：难啊，又被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8ca15329448, createdName=jack123123, createdTime=Wed Jun 03 07:29:34 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=903771, encodeId=7691903e710a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肝癌;药效;靶向治疗 经验分享：注重创新性，审稿很快，效率很高，一审20天，提的意见不多，两个review都肯定了我们的工作，给了一个月补实验，三个星期补完实验，给语言公司润色，当天中午上传修回稿，第二天上午就接受了，简直神速, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Tue Dec 01 09:30:12 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省)]

2024-01-27 P拾荒者来自浙江省

偏重的研究方向：肿瘤
经验分享：邀请了8个审稿人，一周了没人接受审稿，哎，啥个情况

25 15

展开15条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向：肿瘤 经验分享：邀请了8个审稿人，一周了没人接受审稿，哎，啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601231, encodeId=8898601231d3, content=审稿速度:1.0 经验分享：难啊，又被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8ca15329448, createdName=jack123123, createdTime=Wed Jun 03 07:29:34 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=903771, encodeId=7691903e710a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肝癌;药效;靶向治疗 经验分享：注重创新性，审稿很快，效率很高，一审20天，提的意见不多，两个review都肯定了我们的工作，给了一个月补实验，三个星期补完实验，给语言公司润色，当天中午上传修回稿，第二天上午就接受了，简直神速, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Tue Dec 01 09:30:12 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省)]

2020-10-26 Charlo

10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。

214 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向：肿瘤 经验分享：邀请了8个审稿人，一周了没人接受审稿，哎，啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601231, encodeId=8898601231d3, content=审稿速度:1.0 经验分享：难啊，又被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8ca15329448, createdName=jack123123, createdTime=Wed Jun 03 07:29:34 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=903771, encodeId=7691903e710a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肝癌;药效;靶向治疗 经验分享：注重创新性，审稿很快，效率很高，一审20天，提的意见不多，两个review都肯定了我们的工作，给了一个月补实验，三个星期补完实验，给语言公司润色，当天中午上传修回稿，第二天上午就接受了，简直神速, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Tue Dec 01 09:30:12 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省)]

2021-04-25 金鱼的眼泪

4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭

77 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向：肿瘤 经验分享：邀请了8个审稿人，一周了没人接受审稿，哎，啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601231, encodeId=8898601231d3, content=审稿速度:1.0 经验分享：难啊，又被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8ca15329448, createdName=jack123123, createdTime=Wed Jun 03 07:29:34 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=903771, encodeId=7691903e710a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肝癌;药效;靶向治疗 经验分享：注重创新性，审稿很快，效率很高，一审20天，提的意见不多，两个review都肯定了我们的工作，给了一个月补实验，三个星期补完实验，给语言公司润色，当天中午上传修回稿，第二天上午就接受了，简直神速, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Tue Dec 01 09:30:12 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省)]

2020-06-03 jack123123

审稿速度:1.0
经验分享：难啊，又被拒了

137 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向：肿瘤 经验分享：邀请了8个审稿人，一周了没人接受审稿，哎，啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601231, encodeId=8898601231d3, content=审稿速度:1.0 经验分享：难啊，又被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8ca15329448, createdName=jack123123, createdTime=Wed Jun 03 07:29:34 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=903771, encodeId=7691903e710a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肝癌;药效;靶向治疗 经验分享：注重创新性，审稿很快，效率很高，一审20天，提的意见不多，两个review都肯定了我们的工作，给了一个月补实验，三个星期补完实验，给语言公司润色，当天中午上传修回稿，第二天上午就接受了，简直神速, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Tue Dec 01 09:30:12 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省)]

2023-06-03 1473ac4am82暂无昵称来自四川省

偏重的研究方向：肿瘤
经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命

50 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向：肿瘤 经验分享：邀请了8个审稿人，一周了没人接受审稿，哎，啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601231, encodeId=8898601231d3, content=审稿速度:1.0 经验分享：难啊，又被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8ca15329448, createdName=jack123123, createdTime=Wed Jun 03 07:29:34 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=903771, encodeId=7691903e710a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肝癌;药效;靶向治疗 经验分享：注重创新性，审稿很快，效率很高，一审20天，提的意见不多，两个review都肯定了我们的工作，给了一个月补实验，三个星期补完实验，给语言公司润色，当天中午上传修回稿，第二天上午就接受了，简直神速, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Tue Dec 01 09:30:12 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省)]

2020-12-01 泪湿青衣

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：肝癌;药效;靶向治疗
经验分享：注重创新性，审稿很快，效率很高，一审20天，提的意见不多，两个review都肯定了我们的工作，给了一个月补实验，三个星期补完实验，给语言公司润色，当天中午上传修回稿，第二天上午就接受了，简直神速

282 9

展开9条回复

[GetPortalCommentsPageByObjectIdResponse(id=1234363, encodeId=93f81234363f1, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：主动脉夹层 经验分享：5.3 Submitted to Journal 5.4 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 5.10 Under Review 6.10 Required Reviews Completed 6.12 Decision in Process 6.14 Major Revise (20天期限) 7.2 Resubmitted to Journal 7.3 With Editor (此阶段包含inviting reviewers时间，只有inviting reviewers接受邀请才会进入Review阶段) 7.11 Under Review 7.20 Required Reviews Completed 7.20 Decision in Process 7.23 Accept 7.23 Pre-proof online (DOI ) 要点： 1.Pharmacological Research期刊的审稿效率很高，投稿后Editor如果觉得文章质量不高会在当天拒稿，如果投稿当天或者第二天没有decision inprocess，那文章基本上进入Review invitations sent环节，但投稿状态仍然显示With Editor，只有等inviting reviewers同意审稿，投稿状态才会变成Under Review。 2.一审1个月左右，编辑和评审对国人友好，文章语言没经过润色，但返修时编辑和评审都没提文章语言的问题。 3.文章在返修提交时候，系统里会必须要求上传Graphical abstract figure以及Western blot的uncropped images，可以不是全膜，只要把显影结果的条带贴上去并且标出清晰的Marker位置和分子量并将文章全部的Western blot uncropped images保存为word或者pdf上传以供审核 祝各位的Paper早日Accept !!!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=39, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/VfsOucy6VrYLsb3neLZRaBTUd4IVN3oNreMaVjlP3VWic35Mm4gK03LxFrSAviclVf9OeC7wYeyX0gZuRZia1ibxJg/132, createdBy=5a362490022, createdName=石烽, createdTime=Sun Jul 24 11:03:14 CST 2022, time=2022-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=904282, encodeId=6701904282d8, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：一审20天，给了一个月修回，修回后第二天立马接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=360, replyNumber=33, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Wed Dec 02 12:45:00 CST 2020, time=2020-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=907230, encodeId=739690e230a7, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：一审15天，一周修回，2小时后accept，效率奇高, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=391, replyNumber=20, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=481b5433585, createdName=ms1000001706153386, createdTime=Sat Dec 12 08:24:55 CST 2020, time=2020-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2184291, encodeId=f8662184291c8, content=偏重的研究方向：肿瘤 经验分享：邀请了8个审稿人，一周了没人接受审稿，哎，啥个情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f132419863, createdName=P拾荒者, createdTime=Sat Jan 27 14:40:45 CST 2024, time=2024-01-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=894674, encodeId=7d128946e454, content=10.1号提交，10.26号接收，神速啊，感谢审稿人感谢编辑。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=214, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201009/895ae528ae6b499ba49332814baf43e2/f6e090ee0eb54822962fa41fee5269a8.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Mon Oct 26 23:53:17 CST 2020, time=2020-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960480, encodeId=317a9604806c, content=4.21号状态变成required reviews completed ，4.25号还没变化是不是要黄😭, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=3cdf5458328, createdName=金鱼的眼泪, createdTime=Sun Apr 25 22:21:37 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601231, encodeId=8898601231d3, content=审稿速度:1.0 经验分享：难啊，又被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=137, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8ca15329448, createdName=jack123123, createdTime=Wed Jun 03 07:29:34 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2140666, encodeId=e32f2140666ae, content=偏重的研究方向：肿瘤 经验分享：综述，周五晚上9点提交的，周6就under review了是什么情况...慌得要命, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=50, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cb15200587, createdName=1473ac4am82暂无昵称, createdTime=Sat Jun 03 20:16:09 CST 2023, time=2023-06-03, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=903771, encodeId=7691903e710a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：肝癌;药效;靶向治疗 经验分享：注重创新性，审稿很快，效率很高，一审20天，提的意见不多，两个review都肯定了我们的工作，给了一个月补实验，三个星期补完实验，给语言公司润色，当天中午上传修回稿，第二天上午就接受了，简直神速, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/j8ZDGGwXviarvaQUrTnwMAOacKbibaUNYPklS9cSMRgJw3U6lS6gcOeXyON2j21ichZw1g7CU9qdYwnK7sPy0RWLQ/132, createdBy=3fb82251429, createdName=泪湿青衣, createdTime=Tue Dec 01 09:30:12 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2104180, encodeId=a2e9210418014, content=这周刚接受了一篇，速度很快，很爽！！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81b82458851, createdName=1241217bm20暂无昵称, createdTime=Sun Dec 04 00:00:48 CST 2022, time=2022-12-04, status=1, ipAttribution=江苏省)]

2022-12-04 1241217bm20暂无昵称来自江苏省

这周刚接受了一篇，速度很快，很爽！！

59 8

展开8条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务